Answers are grounded in this paper and cite their sources.
Background Diabetic kidney disease (DKD) is a key driver of end-stage renal disease, requiring intensive multidisciplinary care with clinical pharmacists as critical members. Though existing studies confirm pharmacist intervention efficacy, the relationship between intervention intensity and DKD patient outcomes remains poorly defined. Based on prior work, intervention intensity was quantified via two variable categories: (1) Clinical measures: therapeutic regimen optimization, Guideline-Directed Medical Therapy (GDMT) utilization and managing drug-drug interactions/adverse reactions; (2) Management metrics: medication education, physician acceptance of recommendation, medication rationality assessment and patient adherence evaluation. This study aimed to assess the association between clinical pharmacist intervention intensity and DKD patients’ key outcomes and prognosis via data-driven clustering. Methods Retrospective real-world cohort study at a Chinese Grade A tertiary hospital (May 2021–August 2025) assessed 148 inpatients, enrolling 97 patients were stratified via K-means clustering with uniform pharmacist intervention parameters; principal component analysis reduced dimensionality. Primary outcomes: eGFR. Secondary outcomes: UACR, HbA1c, readmission, dialysis initiation, MACE (heart failure, myocardial infarction, stroke, and cardiovascular death.). Results Of 97 inpatients, 58 had low-intensity and 39 had high-intensity clinical pharmacist intervention. Baseline characteristics were similar except for age. Changes from baseline to the 6-month follow-up, patients in the high-intensity group demonstrated significantly greater improvements in eGFR (median: 9.23 vs. −9.92 mL/min/1.73 m 2 , P < 0.05) and more pronounced reductions in UACR (median: −2038.21 vs . −901.92 mg/g, P < 0.05) and HbA1c (median: −1.17 vs. −0.24%, P < 0.05) compared with those in the low-intensity control group. In prognostic analysis, an eGFR decline (threshold: −10 mL/min/1.73 m 2 ) in the low-intensity group increased the incidence of MACE ( P = 0.020). Post hoc analyses identified medium-to-high adherence (OR = 4.058, 95% CI:1.167–14.111, P = 0.028) and ≥7 medication education sessions (OR = 6.250, 95% CI:1.996–17.574, P = 0.002) as independent predictors of eGFR improvement in DKD patients. Moreover, higher GDMT utilization/adherence correlated with greater eGFR improvement. Conclusion This study demonstrates that, compared with low-intensity intervention, high-intensity clinical pharmacist intervention is associated with better renal function and glycemic control, and may offer potential implications for delivering clinical value to high-risk patients. Limitations include the study’s limited follow-up duration and selection bias; future research will require larger samples and extended follow-up to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: